University of Massachusetts Chan Medical School: Phase I Study for Human Monoclonal Antibody for Lyme Disease Demonstrates Safety, Tolerability, Pharmacokinetics
April 01, 2026
April 01, 2026
WORCESTER, Massachusetts, April 1 -- The University of Massachusetts Chan Medical School issued the following news:
* * *
Phase I study for human monoclonal antibody for Lyme disease demonstrates safety, tolerability, pharmacokinetics
By Jim Fessenden
A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting s . . .
* * *
Phase I study for human monoclonal antibody for Lyme disease demonstrates safety, tolerability, pharmacokinetics
By Jim Fessenden
A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting s . . .